Original Article

CME Article: Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD

Authors: Tiffany Yu, BS, Timothy Campbell, BA, Isabella Ciuffetelli, BA, Carlton Haywood, PhD, Christopher Patrick Carroll, MD, Linda Resar, MD, John J. Strouse, MD, PhD, Sophie Lanzkron, MD, MHS

Abstract

Objectives: Sickle cell disease (SCD) is associated with high healthcare utilization rates and poor outcomes in a subset of patients, although the underlying factors that predict this phenotype are poorly understood. Prior studies suggest that comorbid avascular necrosis (AVN) contributes to high healthcare utilization. We sought to clarify whether AVN independently predicts acute care utilization in adults with SCD and to identify characteristics of those with AVN that predict higher utilization.

Methods: We reviewed the medical records of 87 patients with SCD with symptomatic AVN and compared acute care utilization and clinical characteristics with 87 sex- and age-matched patients with SCD without symptomatic AVN. Patients with ≥2 years of follow-up were included. Outcomes were compared using bivariate analysis and multivariate regression.

Results: Our study included 1381 follow-up years, with a median of 7 years per patient. The AVN cohort had greater median rates of urgent care visits (3.2/year vs 1.3/year; P = 0.0155), admissions (1.3/year vs 0.4/year; P = 0.0002), and admission days (5.1 days/year vs 1.8 days/year; P = 0.0007). History of high utilization (odds ratio [OR] 4.28; P = 0.001), acute chest syndrome (OR 3.12; P = 0.005), pneumonia (OR 3.20; P = 0.023), hydroxyurea therapy (OR 2.23; P = 0.0136), and long-term transfusion (OR 2.33; P = 0.014) were associated with AVN. In a median regression model, AVN, acute chest syndrome, and pneumonia were independently associated with greater urgent care visits and admissions.

Conclusions: Symptomatic AVN was found to be an independent risk factor for acute care utilization in patients with SCD. Because this is a potentially modifiable factor, further studies are urgently needed to determine whether AVN prevention/early treatment interventions will alter utilization and improve outcomes for patients with SCD.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Blinder M, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer 2013;60:828-835.
 
2. Carroll CP, Haywood C, Jr Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med 2011;6:248-255.
 
3. Carroll CP, Haywood C, Jr Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009;84:666-670.
 
4. Epstein K, Yuen E, Riggio JM, et al. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc 2006;98:1109-1113.
 
5. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005;84:363-376.
 
6. Akinyoola AL, Adediran IA, Asaleye CM, et al. Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease. Int Orthop 2009;33:923-926.
 
7. Akinyoola AL, Adediran IA, Asaleye CM. Avascular necrosis of the femoral head in sickle cell disease in Nigeria: a retrospective study. Niger Postgrad Med J 2007;14:217-220.
 
8. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476-1481.
 
9. Powars DR, Hiti A, Ramicone E, et al. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol 2002;70:206-215.
 
10. Iwegbu CG, Fleming AF. Avascular necrosis of the femoral head in sickle-cell disease. A series from the Guinea Savannah of Nigeria. J Bone Joint Surg Br 1985;67:29-32.
 
11. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Pres 1993;289:136-143.
 
12. Ware HE, Brooks AP, Toye R, et al. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br 1991;73:947-949.
 
13. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am 2003;85-A:500-504.
 
14. Hernigou P, Habibi A, Bachir D, et al. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am 2006;88:2565-2572.
 
15. Hernigou P, Poignard A, Nogier A, et al. Fate of very small asymptomatic stage-I osteonecrotic lesions of the hip. J Bone Joint Surg Am 2004;86-A:2589-2593.
 
16. Osunkwo I. An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinal Diabetes Obes 2013;20:539-546.
 
17. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288-1294.
 
18. Candrilli SD, O? SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011;8:273-277.
 
19. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009;84:323-327.
 
20. Lanzkron S, Haywood C, Jr Segal JB, et al. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006;81:927-932.
 
21. Lanzkron S, Carroll CP, Haywood C, Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010;85:797-799.
 
22. Okam MM, Shaykevich S, Ebert BL, et al. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care 2014;52:612-618.
 
23. Ezenwa MO, Molokie RE, Wang ZJ, et al. Outpatient pain predicts subsequent one-year acute health care utilization among adults with sickle cell disease. J Pain Symptom Manage 2014;48:65-74.
 
24. Savage WJ, Buchanan GR, Yawn BP, et al. Evidence gaps in the management of sickle cell disease: a summary of needed research. Am J Hematol 2015;90:273-275.
 
25. Hawker H, Neilson H, Hayes RJ, et al. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol 1982;50:29-34.
 
26. Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: current concepts. Indian J Orthop 2015;49:28-45.
 
27. Johannson HR, Zywiel MG, Marker DR, et al. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop 2011;35:465-473.
 
28. Patel YD, Szczech BW, Patel S, et al. Management strategies for total hip arthroplasty in sickle cell patients. J Long Term Eff Med Implants 2014;24:219-224.